MXPA05002617A - Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena. - Google Patents

Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.

Info

Publication number
MXPA05002617A
MXPA05002617A MXPA05002617A MXPA05002617A MXPA05002617A MX PA05002617 A MXPA05002617 A MX PA05002617A MX PA05002617 A MXPA05002617 A MX PA05002617A MX PA05002617 A MXPA05002617 A MX PA05002617A MX PA05002617 A MXPA05002617 A MX PA05002617A
Authority
MX
Mexico
Prior art keywords
epo
erythropoietin
linked
oligosaccharide chain
product
Prior art date
Application number
MXPA05002617A
Other languages
English (en)
Spanish (es)
Inventor
John Smart
Original Assignee
Warren Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warren Pharmaceuticals Inc filed Critical Warren Pharmaceuticals Inc
Publication of MXPA05002617A publication Critical patent/MXPA05002617A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
MXPA05002617A 2002-09-09 2003-09-09 Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena. MXPA05002617A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40902002P 2002-09-09 2002-09-09
PCT/US2003/028073 WO2004022577A2 (fr) 2002-09-09 2003-09-09 Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene

Publications (1)

Publication Number Publication Date
MXPA05002617A true MXPA05002617A (es) 2005-09-08

Family

ID=31978712

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05002617A MXPA05002617A (es) 2002-09-09 2003-09-09 Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.

Country Status (15)

Country Link
EP (1) EP1545586A4 (fr)
JP (1) JP2006511468A (fr)
KR (1) KR20050083682A (fr)
CN (2) CN101371920A (fr)
AU (1) AU2003273297A1 (fr)
BR (1) BR0314152A (fr)
CA (1) CA2497960A1 (fr)
EA (1) EA007812B1 (fr)
IL (1) IL174178A0 (fr)
IS (1) IS7731A (fr)
MX (1) MXPA05002617A (fr)
NO (1) NO20051714L (fr)
PL (1) PL375741A1 (fr)
WO (1) WO2004022577A2 (fr)
ZA (1) ZA200505423B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2006061853A2 (fr) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Nouveaux composes erythropoietiques et leur procede de production
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
CA3079319A1 (fr) 2005-08-05 2007-02-15 Araim Pharmaceuticals, Inc. Peptides protecteurs de tissus et leurs utilisations
SG10202011946PA (en) 2008-01-22 2020-12-30 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN101671388B (zh) * 2008-09-09 2013-01-02 曹国栋 血脑屏障穿透性促红细胞生成素及其应用
RU2475273C1 (ru) * 2012-04-02 2013-02-20 Юлия Николаевна Козлова Способ получения полимерного цемента медицинского назначения
CN102746405B (zh) * 2012-07-24 2013-08-21 深圳赛保尔生物药业有限公司 重组人促红素的连续聚乙二醇化反应方法
RU2664588C2 (ru) * 2015-11-05 2018-08-21 Закрытое Акционерное Общество "Биокад" Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе
EP3448415A4 (fr) 2016-04-29 2019-11-06 Araim Pharmaceuticals, Inc. Peptides protecteurs tissulaires permettant de prévenir et traiter des maladies et des troubles associés à une lésion tissulaire
CN112741895A (zh) * 2021-01-19 2021-05-04 中国人民解放军陆军军医大学 Epo类似物在制备治疗脓毒症药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
WO2001081405A2 (fr) * 2000-04-21 2001-11-01 Amgen Inc. Methodes et compositions destinees a la prevention et au traitement de l'anemie
DK1311285T4 (en) * 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative

Also Published As

Publication number Publication date
CN1729015A (zh) 2006-02-01
IS7731A (is) 2005-03-08
AU2003273297A8 (en) 2004-03-29
IL174178A0 (en) 2006-08-01
NO20051714L (no) 2005-06-06
EP1545586A4 (fr) 2007-09-26
BR0314152A (pt) 2005-07-12
AU2003273297A1 (en) 2004-03-29
KR20050083682A (ko) 2005-08-26
CA2497960A1 (fr) 2004-03-18
EA007812B1 (ru) 2007-02-27
ZA200505423B (en) 2008-08-27
EP1545586A2 (fr) 2005-06-29
EA200500473A1 (ru) 2005-10-27
PL375741A1 (en) 2005-12-12
JP2006511468A (ja) 2006-04-06
WO2004022577A3 (fr) 2004-09-16
CN101371920A (zh) 2009-02-25
WO2004022577A2 (fr) 2004-03-18

Similar Documents

Publication Publication Date Title
US20050176627A1 (en) Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2005025606A1 (fr) Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
KR100985615B1 (ko) 에리트로포이에틴-응답 세포, 조직 및 기관의 보호, 회복 및 향상
US7767643B2 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EA015672B1 (ru) Тканезащитные пептиды и их применения
JP2006512326A (ja) 心臓疾患におけるエリスロポエチンの新規な使用
AU2002239665A1 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EA010200B1 (ru) Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
JP2008067699A (ja) 截形グリア細胞系由来神経栄養因子
US20040209812A1 (en) Use of erythropoietin in stroke recovery
MXPA05002617A (es) Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.
US11767344B2 (en) Pharmaceutically acceptable salts of polypeptides and methods of inhibiting the interaction between psd-95 and n-methyl-d-aspartic acid receptor (nmdar)
US20040077543A1 (en) Treatment using neublastin polypeptides
JPH083058A (ja) 新規な骨代謝疾患治療剤
AU2004260543A8 (en) Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
KR20060132803A (ko) 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는장기 작용성 에리트로포이에틴
ZA200508695B (en) Use of erythropoietin in stroke recovery